Featured
Bimeda Ireland Participated in the Vet24 Conference
Around 300 delegates attended the event which gave our commercial team the chance to discuss our range with customers, build new relationships and strengthen Bimeda's image.
Bimacox was officially launched to our customers ahead of commercial release. This was a great opportunity to talk about the product features and advantages. Bimacox 2.5mg/ml is an oral suspension for sheep and cattle containing diclazuril. Bimacox is licensed for the prevention of key pathogenic coccidial strains including Eimeria crandallis and Eimeria ovinoidalis in lambs and Eimeria bovis and Eimeria zuernii in calves. Bimacox is a POM medicine.
Rachel Mallet, Bimeda Veterinarian commented "the impact of coccidiosis for our clients can be staggering considering not only treatment costs but lost productivity both in the short and long term. The targeted and responsible use of anti-coccidial medicines, when necessary, along with good management, supports efficient protein production".
One of the key benefits of utilizing this solution, is that it allows immune exposure to the coccidia parasites while halting their reproduction and reducing subsequent environmental contamination and risk. Affected individuals will therefore still be able to build immune resilience allowing for sustainable control.
General Manager, Andrew Glynn, commented: "At Bimeda we focus on providing high quality solutions which address the needs of our customers. Parasite control is an area of critical importance, and we are delighted to make this solution available to our customers."
Bimacox 2.5 mg/ml Oral Suspension for Sheep and Cattle is a POM medicine containing 2.5mg/ml diclazuril. It is licensed for the prevention of clinical signs of coccidiosis caused by Eimeria crandallis and Eimeria ovinoidalis in lambs and Eimeria bovis and Eimeria zuernii in calves. For further information see the SPC available on the HPRA website. Advice should be sought from the prescriber. September 2024.